糖尿病躯干神经病1例报道

2019-02-20 吴思,张晗,张晓天,郑东明 国际神经病学

糖尿病躯干神经病是糖尿病周围神经病的一种特殊类型,其特点是急性发作的呈节段性分布的胸腹部疼痛,临床较为少见,容易误诊误治,现将我科收治的1例糖尿病躯干神经病报道如下,并结合文献对其临床表现、诊断及治疗进行讨论,以期能指导今后的临床工作。

糖尿病躯干神经病是糖尿病周围神经病的一种特殊类型,其特点是急性发作的呈节段性分布的胸腹部疼痛,临床较为少见,容易误诊误治,现将我科收治的1例糖尿病躯干神经病报道如下,并结合文献对其临床表现、诊断及治疗进行讨论,以期能指导今后的临床工作。

01.病例资料

患者,男,66岁,以“前胸后背部疼痛8个月”为主诉入院。患者8个月前开始出现左侧髋部疼痛,后疼痛范围蔓延至双侧胸腹及后背部,向上达腋下水平,向下达腹股沟水平。疼痛为持续性,呈烧灼、针刺感,皮肤受到外界触碰如衣物接触时疼痛加重,以至于患者经常赤裸上身。疼痛程度较为剧烈,影响睡眠。曾就诊我院疼痛科,给予营养神经、口服药物止痛、椎旁神经阻滞及CT引导下周围神经毁损术(T5-T9)等治疗,疼痛未见明显缓解。既往糖尿病病史1年,皮下注射胰岛素治疗。否认疱疹病史。否认长期饮酒史。入院查体:胸4至胸10水平痛觉减退,四肢腱反射均不能引出,余查体未见异常。入院化验空腹血糖7.79mmol/L,餐后2小时血糖11.18mmol/L,糖化血红蛋白7.0%,其余常规生化、抗核抗体系列等风湿指标及全身肿瘤标志物检查未见异常。头MRI平扫、颈椎和胸椎MRI增强、全腹增强CT及全身骨静态显像均未见异常。肌电图提示四肢周围神经损害,感觉和运动神经均受累,以感觉纤维损害为主。感觉定量分析肌电图显示胸部T4皮区至腹部T10皮区轻度至中度感觉减退。综上,诊断考虑为糖尿病躯干神经病。予患者加巴喷丁(开始时,300mg/次,每日3次,口服,后逐渐增量至900mg/次,每日3次,口服)、盐酸氢考酮(325mg/次,每间隔8h一次,口服)、盐酸曲马多(100mg/次,每日1次,口服)和文拉法辛(225mg/次,每日1次,口服)止痛治疗,严格控制患者血糖水平,同时予营养神经和改善循环治疗。用药2周后患者疼痛症状略有好转,出院后继续口服药物治疗。

02.讨论

糖尿病躯干神经病主要表现为急性发作的呈节段性分布的胸腹部疼痛。由于缺乏准确的定位可有不同的名称,如糖尿病胸腹神经根病、糖尿病肋间神经痛和糖尿病假内脏综合征等。该病多累及中下部胸段(胸8至胸12节段),可呈单侧或双侧分布。急慢性起病者均有,以急性起病者较常见。可单独发生,亦可伴随其他的糖尿病并发症,如对称性多神经病和糖尿病脑病等。该病易与胸腹腔脏器病变引起的牵涉痛及脊髓疾病相混淆,需注意鉴别。疾病的定位仍有争议,可能累及脊髓的背根神经节、脊神经根、混合型脊神经、胸部肋间神经后肢和腹神经。呈皮肤节段性分布的多提示累及脊髓背根神经节或脊神经。皮肤活检可用来评估神经纤维损伤严重程度。

糖尿病躯干神经病的治疗主要是在严格控制血糖和营养周围神经的基础之上,给与止痛治疗。不同临床指南所推荐的1线及2线用药有所不同,但多数指南均推荐三环类药物、色氨酸再摄取抑制剂(如文拉法辛)及γ氨基丁酸类似物(如加巴喷丁及瑞普巴林)作为一线用药,阿片类(曲马多及羟考酮)及局部用药(如辣椒素)作为二线用药。在临床应用中,联合用药可能效果更好。非药物止痛方法包括经皮电神经刺激术及经皮电神经和频率调整的电磁神经刺激术,可以在药物治疗的基础之上配合进行。该病预后良好,疼痛症状通常在治疗后3-12个月有所缓解。本例患者跟踪半年,疼痛症状控制良好。

综上,糖尿病躯干神经病临床上比较少见,临床医生应该对此加强认识。在进行充分检查排除其他疾病的基础之上,应给与积极的止痛治疗。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=361618, encodeId=81a0361618e1, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 27 18:11:02 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491337, encodeId=9462149133e90, content=<a href='/topic/show?id=5316e4387aa' target=_blank style='color:#2F92EE;'>#神经病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74387, encryptionId=5316e4387aa, topicName=神经病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ab48885684, createdName=axin012, createdTime=Fri Feb 22 14:15:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361261, encodeId=719d3612615e, content=大作已经学习,谢谢把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Fri Feb 22 12:30:11 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361164, encodeId=35d33611648a, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Feb 21 08:11:05 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042270, encodeId=790e10422e0eb, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Feb 21 02:15:00 CST 2019, time=2019-02-21, status=1, ipAttribution=)]
    2019-02-27 jyzxjiangqin

    糖尿病患者的治疗。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=361618, encodeId=81a0361618e1, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 27 18:11:02 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491337, encodeId=9462149133e90, content=<a href='/topic/show?id=5316e4387aa' target=_blank style='color:#2F92EE;'>#神经病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74387, encryptionId=5316e4387aa, topicName=神经病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ab48885684, createdName=axin012, createdTime=Fri Feb 22 14:15:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361261, encodeId=719d3612615e, content=大作已经学习,谢谢把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Fri Feb 22 12:30:11 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361164, encodeId=35d33611648a, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Feb 21 08:11:05 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042270, encodeId=790e10422e0eb, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Feb 21 02:15:00 CST 2019, time=2019-02-21, status=1, ipAttribution=)]
    2019-02-22 axin012
  3. [GetPortalCommentsPageByObjectIdResponse(id=361618, encodeId=81a0361618e1, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 27 18:11:02 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491337, encodeId=9462149133e90, content=<a href='/topic/show?id=5316e4387aa' target=_blank style='color:#2F92EE;'>#神经病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74387, encryptionId=5316e4387aa, topicName=神经病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ab48885684, createdName=axin012, createdTime=Fri Feb 22 14:15:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361261, encodeId=719d3612615e, content=大作已经学习,谢谢把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Fri Feb 22 12:30:11 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361164, encodeId=35d33611648a, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Feb 21 08:11:05 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042270, encodeId=790e10422e0eb, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Feb 21 02:15:00 CST 2019, time=2019-02-21, status=1, ipAttribution=)]
    2019-02-22 1dd8a7c5m95(暂无匿称)

    大作已经学习,谢谢把经验分享给同好。点赞了!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=361618, encodeId=81a0361618e1, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 27 18:11:02 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491337, encodeId=9462149133e90, content=<a href='/topic/show?id=5316e4387aa' target=_blank style='color:#2F92EE;'>#神经病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74387, encryptionId=5316e4387aa, topicName=神经病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ab48885684, createdName=axin012, createdTime=Fri Feb 22 14:15:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361261, encodeId=719d3612615e, content=大作已经学习,谢谢把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Fri Feb 22 12:30:11 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361164, encodeId=35d33611648a, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Feb 21 08:11:05 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042270, encodeId=790e10422e0eb, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Feb 21 02:15:00 CST 2019, time=2019-02-21, status=1, ipAttribution=)]
    2019-02-21 龙胆草

    学习谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=361618, encodeId=81a0361618e1, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 27 18:11:02 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491337, encodeId=9462149133e90, content=<a href='/topic/show?id=5316e4387aa' target=_blank style='color:#2F92EE;'>#神经病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74387, encryptionId=5316e4387aa, topicName=神经病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ab48885684, createdName=axin012, createdTime=Fri Feb 22 14:15:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361261, encodeId=719d3612615e, content=大作已经学习,谢谢把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Fri Feb 22 12:30:11 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361164, encodeId=35d33611648a, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Feb 21 08:11:05 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042270, encodeId=790e10422e0eb, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Feb 21 02:15:00 CST 2019, time=2019-02-21, status=1, ipAttribution=)]
    2019-02-21 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

JAHA:成人与糖尿病相关的全因和心血管死亡率分析

由此可见,糖尿病仍然与全因和心血管疾病死亡率显著相关,尽管糖尿病相关的过量死亡率在当代比以前更低。研究人员观察到死亡风险梯度随着HbA1c从6%增加到6.9%,表明即使不能推断出因果关系,HbA1c仍然是患者结局的预测因素。

JAMA Netw Open:肠道细菌更能决定餐后血糖水平

研究人员还指出,越来越多的证据表明,食用同一种食物后,不同的个体的血糖水平变化显着不同。

真实病例分享:心衰合并糖尿病、肾功能不全,怎么办?

沙库巴曲缬沙坦钠片治心衰的同时还可带来血糖获益;并使糖尿病患者肾小球滤过率(eGFR)下降速率明显减缓,令心衰合并糖尿病患者获益更大。

JACC:糖尿病患者多支血管病变的长期存活率

近日,JACC发表的一项研究评估在FREEDOM试验中接受冠状动脉血运重建的MVD患者的长期存活率。

JCEM:二甲双胍在银屑病糖尿病患者中的安全性分析

由此可见,二甲双胍可用于治疗糖尿病性银屑病患者,无需担心安全问题。

PNAS:都说糖尿病和老年痴呆有关,原因你可能还不知道

一项最新研究表明,大脑中胰岛素信号受损可能会对认知、情绪和代谢产生不利影响,而这些都是阿尔茨海默病的常见症状。